ATE296305T1 - Antioxidantien mit spezifischer wirkung auf mitochondrien - Google Patents

Antioxidantien mit spezifischer wirkung auf mitochondrien

Info

Publication number
ATE296305T1
ATE296305T1 AT98961702T AT98961702T ATE296305T1 AT E296305 T1 ATE296305 T1 AT E296305T1 AT 98961702 T AT98961702 T AT 98961702T AT 98961702 T AT98961702 T AT 98961702T AT E296305 T1 ATE296305 T1 AT E296305T1
Authority
AT
Austria
Prior art keywords
compounds
mitochondria
antioxidants
antioxidant
specific effect
Prior art date
Application number
AT98961702T
Other languages
English (en)
Inventor
Michael Patrick Murphy
Robin A J Smith
Original Assignee
Antipodean Biotechnology Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Antipodean Biotechnology Ltd filed Critical Antipodean Biotechnology Ltd
Application granted granted Critical
Publication of ATE296305T1 publication Critical patent/ATE296305T1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/547Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/655Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms
    • C07F9/6552Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms the oxygen atom being part of a six-membered ring
    • C07F9/65522Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms the oxygen atom being part of a six-membered ring condensed with carbocyclic rings or carbocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/543Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00General protective or antinoxious agents
    • A61P39/06Free radical scavengers or antioxidants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/28Phosphorus compounds with one or more P—C bonds
    • C07F9/54Quaternary phosphonium compounds
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/547Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/553Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
    • C07F9/572Five-membered rings
    • CCHEMISTRY; METALLURGY
    • C09DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
    • C09BORGANIC DYES OR CLOSELY-RELATED COMPOUNDS FOR PRODUCING DYES, e.g. PIGMENTS; MORDANTS; LAKES
    • C09B69/00Dyes not provided for by a single group of this subclass
    • C09B69/001Dyes containing an onium group attached to the dye skeleton via a bridge

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Cosmetics (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Saccharide Compounds (AREA)
  • Anti-Oxidant Or Stabilizer Compositions (AREA)
  • Preventing Corrosion Or Incrustation Of Metals (AREA)
AT98961702T 1997-11-25 1998-11-25 Antioxidantien mit spezifischer wirkung auf mitochondrien ATE296305T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
NZ32925597 1997-11-25
PCT/NZ1998/000173 WO1999026954A1 (en) 1997-11-25 1998-11-25 Mitochondrially targeted antioxidants

Publications (1)

Publication Number Publication Date
ATE296305T1 true ATE296305T1 (de) 2005-06-15

Family

ID=19926531

Family Applications (1)

Application Number Title Priority Date Filing Date
AT98961702T ATE296305T1 (de) 1997-11-25 1998-11-25 Antioxidantien mit spezifischer wirkung auf mitochondrien

Country Status (12)

Country Link
EP (1) EP1047701B1 (de)
JP (1) JP4590523B2 (de)
CN (1) CN1318434C (de)
AT (1) ATE296305T1 (de)
AU (2) AU763179B2 (de)
CA (1) CA2311318C (de)
DE (1) DE69830338T2 (de)
DK (1) DK1047701T3 (de)
ES (1) ES2244104T3 (de)
NZ (1) NZ505352A (de)
PT (1) PT1047701E (de)
WO (2) WO1999026954A1 (de)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999037294A2 (en) * 1998-01-26 1999-07-29 Mitokor Mitochondria protecting agents for treating mitochondria associated diseases
WO2005019232A1 (en) * 2003-08-22 2005-03-03 Antipodean Pharmaceuticals, Inc. Mitoquinone derivatives used as mitochondrially targeted antioxidants
CA2354743A1 (en) * 2001-08-07 2003-02-07 University Of Otago Mitochondrially targeted antioxidants
CA2397684A1 (en) * 2002-08-12 2004-02-12 Michael P. Murphy Mitochondrially targeted antioxidants
US7888334B2 (en) 2003-08-22 2011-02-15 Antipodean Pharmaceuticals, Inc. Mitoquinone derivatives used as mitochondrially targeted antioxidants
IL173807A (en) 2003-08-22 2014-02-27 Antipodean Pharmaceuticals Inc Antioxidant amphiphilic compounds, histoquinone history and pharmaceutical preparations containing them
NZ528966A (en) * 2003-10-17 2006-11-30 Otago Innovation Ltd Peptide nucleic acid conjugates and uses thereof
JP2007532491A (ja) 2004-04-09 2007-11-15 ヴァロリゼーション−レセルシェ, ソシエテ エン コマンディテ ホスホニウム塩誘導体とその溶解度調節助剤としての使用
RU2318500C2 (ru) * 2005-10-18 2008-03-10 Общество С Ограниченной Ответственностью "Митотехнология" Способ воздействия на организм путем адресной доставки биологически активных веществ в митохондрии, фармацевтическая композиция для его осуществления и соединение, применяемое для этой цели
US9045505B2 (en) 2006-09-28 2015-06-02 University Of Otago Nitric oxide donors
EP2119436A4 (de) * 2006-10-20 2010-03-03 Ltd Liability Company Mitotech Pharmazeutische zusammensetzungen zur verhinderung und behandlung von augenkrankheiten
EA200900583A1 (ru) 2006-10-20 2009-08-28 Общество С Ограниченной Ответственностью "Митотехнология" Композиция для регенерации, стимуляции роста и адаптации растений к различным стрессовым факторам
US9427444B2 (en) 2007-01-29 2016-08-30 Mitotech Sa Pharmaceutical and cosmetic compositions for accelerated healing of wounds and other surface damages
US8349902B2 (en) 2007-01-29 2013-01-08 Mitotech Sa Pharmaceutical compositions useful for preventing and treating oncological diseases
US9439916B2 (en) 2007-04-11 2016-09-13 Mitotech Sa Composition for decelerating the aging in the organism and for extending the life time thereof and the use of said composition
US8518915B2 (en) 2007-06-29 2013-08-27 Mitotech Sa Use of mitochondrially-addressed compounds for preventing and treating cardiovascular diseases
CA2719658C (en) * 2008-04-01 2019-10-01 Antipodean Pharmaceuticals, Inc. Compositions and methods for skin care
WO2010056145A1 (ru) 2008-11-12 2010-05-20 Общество С Ограниченной Ответственностью "Митотехнология" Способ умеренного повышения протонной проводимости биологических мембран при помощи митохондриально- адресованных делокализованных катионов
EP2441453B1 (de) 2009-06-10 2014-11-26 Mitotech SA Pharmazeutische zusammensetzung für die human- und tiermedizinische ophthalmologie
BR112012011197A2 (pt) 2009-11-13 2020-10-20 Obschestvo S Ogranichennoi Otvetsvennostyu "Mitotekh" subtâncias farmacêuticas com base em antioxidantes direcionados à mitocôndria
EA031399B1 (ru) 2011-06-03 2018-12-28 Общество С Ограниченной Ответственностью "Митотех" Изготовление и использование пероральных фармацевтических композиций на основе митохондриально-адресованных антиоксидантов
WO2015063553A2 (en) * 2013-04-11 2015-05-07 Mitotech S.A. Mitochondrially-targeted timoquinones and toluquinones
CN105939601B (zh) * 2014-01-30 2020-03-10 豪夫迈·罗氏有限公司 在室温稳定全血
US9314457B2 (en) 2014-06-19 2016-04-19 The University Of Utah Research Foundation Methods of treating and preventing vascular instability diseases
CN105833289B (zh) * 2016-05-30 2019-04-09 上海交通大学 一种线粒体靶向的纳米药物递送***及其制备方法与应用
EP3612543B1 (de) * 2017-04-20 2022-11-23 Rising Tide Foundation Ein phosphonium-ion enthaltende azithromycin-derivate als antikrebsmittel
CA3060892A1 (en) * 2017-04-20 2018-10-25 Rising Tide Foundation Azithromycin derivatives containing a phosphonium ion as anticancer agents
US11161862B2 (en) 2017-04-20 2021-11-02 Oxford University Innovation Limited Phosphonium-ion tethered tetracycline drugs for treatment of cancer
US11098073B2 (en) 2017-04-20 2021-08-24 Oxford University Innovation Limited Triphenylphosphonium-tethered tetracyclines for use in treating cancer
EP3612187B1 (de) 2017-04-21 2022-04-13 Lunella Biotech, Inc. Vitamin c und doxycyclin: eine synthetische letale kombinationstherapie zur eradikation von krebsstammzellen (cscs)
US11229657B2 (en) 2017-04-21 2022-01-25 Lunella Biotech, Inc. Targeting hypoxic cancer stem cells (CSCs) with doxycycline: implications for improving anti-angiogenic therapy
US12006553B2 (en) 2017-05-19 2024-06-11 Lunella Biotech, Inc. Companion diagnostics for mitochondrial inhibitors
WO2018213751A1 (en) 2017-05-19 2018-11-22 Lunella Biotech, Inc. Antimitoscins: targeted inhibitors of mitochondrial biogenesis for eradicating cancer stem cells
WO2019002936A2 (en) 2017-06-26 2019-01-03 Mitotech S.A. SET OF COMPOUNDS TARGETING MITOCHONDRIA
MX2019014806A (es) 2017-06-26 2020-02-10 Lunella Biotech Inc Mitocetoscinas: agentes terapeuticos basados en mitocondrias que fijan como objetivo el metabolismo de cetonas en celulas cancerosas.
CN109293698B (zh) * 2018-10-15 2021-02-02 山西大学 一种基于苯并噻唑的线粒体pH荧光探针及其制备方法
CN110016048B (zh) * 2019-04-26 2020-06-30 山东大学 线粒体靶向ir780碘化物的衍生物及制备方法与应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3532667A (en) * 1967-05-31 1970-10-06 Du Pont Polyamides stabilized with phosphonium halides
EP0535283A1 (de) * 1991-10-02 1993-04-07 Merrell Dow Pharmaceuticals Inc. Tocopherol Analoge mit kardioprotektiver Wirkung
CA2354743A1 (en) * 2001-08-07 2003-02-07 University Of Otago Mitochondrially targeted antioxidants

Also Published As

Publication number Publication date
JP2001524483A (ja) 2001-12-04
CN1318434C (zh) 2007-05-30
NZ505352A (en) 2002-12-20
PT1047701E (pt) 2005-10-31
DE69830338D1 (de) 2005-06-30
WO1999026954A1 (en) 1999-06-03
JP4590523B2 (ja) 2010-12-01
AU763179B2 (en) 2003-07-17
CA2311318C (en) 2011-11-01
DK1047701T3 (da) 2005-08-15
WO1999026582A2 (en) 1999-06-03
ES2244104T3 (es) 2005-12-01
CA2311318A1 (en) 1999-06-03
EP1047701A1 (de) 2000-11-02
AU1696599A (en) 1999-06-15
CN1282334A (zh) 2001-01-31
DE69830338T2 (de) 2006-02-02
EP1047701A4 (de) 2002-03-27
AU1696499A (en) 1999-06-15
EP1047701B1 (de) 2005-05-25

Similar Documents

Publication Publication Date Title
DE69830338D1 (de) Antioxidantien mit spezifischer wirkung auf mitochondrien
HUP0002454A2 (hu) D-Vitamin-molekularésszel rendelkező konjugátumok és ilyen konjugátumokat tartalmazó gyógyászati készítmények
CO4940450A1 (es) Formulaciones farmaceuticas que contienen voriconazol
BR9905977A (pt) Moduladores de ccr5
DK1033981T3 (da) Formuleringer og fremgangsmåder til nedsættelse af antineoplastiske midlers toksicitet
ES2171533T3 (es) Composiciones que contienen nebivolol micronizado.
ES2130452T3 (es) Derivados de ciclobutano utilizados como inhibidores de la escualeno-sintetasa y de la farnesiltransferasa proteica.
BR0206955A (pt) Ligantes de receptores de canabinóides
LU91145I9 (de)
AU7026794A (en) Phosphonooxymethyl ethers of taxane derivatives
ES2162304T3 (es) Preparaciones cosmeticas y/o farmaceuticas.
ES2166823T3 (es) Nuevos derivados pirrolicos, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen.
PT97905A (pt) Processo para a preparacao de composicoes farmaceuticas contendo derivados da cistina
ES2108772T3 (es) Derivados de aminofosfonato substituidos, procedimiento para su preparacion y composiciones farmaceuticas que los contienen.
MX9202544A (es) Compuestos de diaminoftalimidas substituidas y analogas, procedimiento para su preparacion y preparados farmaceuticos que los contienen.
ES2077549T1 (es) Composiciones dermatologicas que contienen derivados de estilbeno para la proteccion frente a la radiacion uv.
DE69414810D1 (de) Rapamycin-Zubereitungen zur oralen Verabreichung
BR9911250A (pt) Processo para preparação de compostos
CA2274133A1 (fr) Nouveaux derives tetrahydropyridiniques substitues, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
ES2192018T3 (es) Composicion farmaceutica que contiene estimuladores de interferon-gamma.
PT745081E (pt) Derivados de dissulfureto de inda-2-mercaptoacetilamida uteis como inibidores da encefalinase
SE8602060D0 (sv) Farmaceutiska kompositioner som innehaller reducerad glutation
ES2104295T3 (es) Derivados ciclopeptidicos de la angiopeptina, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen.
FR2591591B1 (fr) Alkylcarboxamides de pyridylalkylamines, leurs preparations et leur utilisation en tant que medicaments
ES2118340T3 (es) Nuevos derivados de benzo-espiro-alquenos, su procedimiento de preparacion y composiciones farmaceuticas que los contienen.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1047701

Country of ref document: EP

EEIH Change in the person of patent owner